Emalex Biosciences, Inc., a Chicago, IL-based biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, raised $35m in Series C funding.
The round was led by Paragon Biosciences with participation from Fidelity Management & Research Company LLC and Valor Equity Partners.
The company intends to use the funds to continue to develop its critical work as it pursues an effective drug therapy for people living with Tourette syndrome and childhood-onset fluency disorder (stuttering)—two conditions with high unmet needs.
Emalex Biosciences is a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders with limited or no treatment options. Aligned with its mission, the company is evaluating treatments for childhood-onset fluency disorder(stuttering), and for children and adolescents with Tourette syndrome.
Currently, there are three Phase 2 clinical trials underway at Emalex to evaluate the efficacy and safety of its investigational first-in-class medicine, ecopipam (EBS-101). The round also supports organizational operations through trial completion which is expected by the end of this year.